Acadia Pharmaceuticals Inc. (ACAD) Patent Allowance Extends Trofinetide Protection to 2041

USPTO issued a Notice of Allowance for Acadia’s patent on weight-banded dosing of trofinetide, expected to protect DAYBUE in the U.S. through Mar 28, 2041, including six months pediatric exclusivity. Current method-of-use patent expires July 2036.Material DetailsContext by AI AnalystThis is a mid-c…